In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


French set up expert groups on emerging technology:

This article was originally published in Clinica

Executive Summary

The French healthcare products safety agency, AFSSaPS, has set up three expert groups to ensure that it has at its fingertips the necessary responses to problems related to cutting-edge developments in healthcare techniques and materials. The first will assess applications for gene therapy clinical trials, investigate any "undesirable effects" of such investigations and give an opinion on any related questions likely to arise in biomedical research. The second, on cell therapy (excluding haematopoietic stems cells intended for haematopoietic reconstitution) will have a similar brief. The third is a working group on non-clinical aspects of healthcare products, which will review the techniques used in toxicology to define good practice requirements that may eventually be incorporated into new regulations.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts